Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.9%

7 terminated/withdrawn out of 71 trials

Success Rate

87.7%

+1.2% vs industry average

Late-Stage Pipeline

34%

24 trials in Phase 3/4

Results Transparency

48%

24 of 50 completed trials have results

Key Signals

9 recruiting24 with results6 terminated

Enrollment Performance

Analytics

N/A

18(27.7%)

Phase 3

15(23.1%)

Phase 2

12(18.5%)

Phase 1

11(16.9%)

Phase 4

9(13.8%)

65Total

N/A(18)

Phase 3(15)

Phase 2(12)

Phase 1(11)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (71)

Showing 20 of 71 trials

NCT07169695Phase 2Recruiting

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Role: lead

NCT07522242Phase 2Recruiting

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

Role: lead

NCT06627179Phase 2Recruiting

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Role: lead

NCT06891443Phase 3Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Role: lead

NCT05965778Not ApplicableCompleted

Performance and Safety of T2769 in DED

Role: lead

NCT06394973Phase 2Completed

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Role: lead

NCT06375499Not ApplicableCompleted

Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Role: lead

NCT04499820Not ApplicableCompleted

Effect of OMEGA3 Supplementation in Diabetic Retinopathy

Role: collaborator

NCT07234292Not Yet Recruiting

Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery.

Role: lead

NCT06903741Phase 4Recruiting

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Role: lead

NCT07234318Not Yet Recruiting

Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears

Role: lead

NCT07206628Recruiting

Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®

Role: lead

NCT07007702Completed

Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease

Role: lead

NCT05668455Phase 3Recruiting

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Role: collaborator

NCT05931861Not ApplicableCompleted

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Role: lead

NCT03913130Phase 1Terminated

Extension Study to Study PQ-110-001 (NCT03140969)

Role: lead

NCT03140969Phase 1Completed

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Role: lead

NCT05085964Phase 2Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Role: lead

NCT05176717Phase 2Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Role: lead

NCT05397600Phase 3Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Role: lead